Company intelligence / Profile preview

Ornovi

Irvine, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Ornovi is developing selective JAK3/ITK dual inhibitors for inflammatory and autoimmune diseases. Their lead candidate, OR-101, has shown positive preclinical efficacy in animal models for alopecia areata and other skin conditions. The company reported stimulation of hair growth in murine models with their next-generation JAK3 inhibitor. No clinical results have been published yet.

Therapeutic areas: ImmunologyDermatology
Modalities: Small moleculesMonoclonal antibodies
Industry: Biotech

Drug pipeline

2 assets

OR-102

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Ornovi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ornovi.

Explore the full profile